Response of T-cell posttransplantation lymphoproliferative disorder to lenalidomide therapy. The response to therapy is depicted as absolute lymphocyte count. Patient had treatment failures to fludarabine; cyclophosphomide, prednisone, and vincristine (CVP), and cyclophosphomide, doxorubicin, prednisone, and vincristine (CHOP). Alemtuzumab resulted in a partial hematologic response before relapse. Lenalidomide resulted in a complete hematologic response. She ultimately was unable to tolerate lenalidomide therapy, resulting in disease progression and death.